December 2016
-
ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said.… Read more . . .
-
According to Synairgen, the external data safety monitoring board (DSMB) for the ACTIV-2 study of the company’s SNG001 nebulized interferon beta in mild to moderate COVID-19 patients has recommended that the company advance SNG001 into… Read more . . .
-
Shandong Luoxin Pharmaceutical will pay $2 million up front plus milestone payments of up to $20 million to acquire exclusive rights to develop, manufacture, and commercialize Marninomed’s Budesolv budesonide nasal spray in China, the company has… Read more . . .
-
Aptar Pharma will co-develop and promote i2c Pharmaceutical Services’ Respitab MDI technology, the two companies have announced. The Respitab system involves formulating the drug as a tablet that can be easily dispensed into an MDI… Read more . . .
-
Canadian Biotech Immune Biosolutions said it has initiated a Phase 1 clinical trial of its IBIO123 inhaled antibody therapy, which it is developing for the treatment of COVID-19. According to the company, the trial is… Read more . . .
-
Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec’s mSAS supercritical fluid particle engineering technology. The first… Read more . . .
-
Device maker Nemera announced that it has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as the consortium’s 9th associate member. Other companies that have joined as associate members in the past… Read more . . .
-
United Therapeutics said that the FDA has issued a complete response letter regarding the company’s NDA for Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung… Read more . . .
-
According to Oyster Point Pharma, the FDA has approved the company’s Tyrvaya (OC-01) varenicline nasal spray for the treatment of dry eye disease, and Oyster Point expects to launch the nasal spray in November 2021.… Read more . . .
-
Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer’s NDA… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland